India: Patent

Every 26 April, the world marks World Intellectual Property Day, the date on which the Convention Establishing the World Intellectual Property Organization (WIPO) entered into force in 1970. Since 2000, WIPO has used this occasion to raise awareness of how IP and sports innovation, creativity, and brand identity shape daily life, reward creators, and fuel economies across the globe.

企业在印度市场布局专利时，常因不熟悉当地年费规则而导致专利权意外失效。本文深入解析印度专利年费的缴费规则、时间节点、逾期处理机制

Most enterprises entering India through a BOT structure spend weeks negotiating hiring plans, transition timelines, pricing models, and operational governance. Then the agreement gets signed, the build phase begins, and business heads assume the difficult part is over.

The Indian Arbitration Act, 1996, is international in its outlook. It is founded on two United Nations documents: the UNCITRAL Rules of 1976 and the UNCITRAL Model Law of 1985. India adopted these blueprints for its international and also its domestic arbitrations.

In today’s digital economy, innovation no longer resides solely in tangible machines or physical products, it increasingly lies in lines of code, layered interfaces, and seamless user experiences. As global platforms race to roll out new features at scale, a crucial question emerges: where does innovation end and infringement begin?

The case raises a central question: to what extent can public interest influence the grant and scope of injunctive relief in cases involving deceptively similar medicinal trademarks?

In an era where intellectual property strategy increasingly determines competitive advantage, Geographical Indications and Sustainable Regional Development have emerged as a powerful yet underleveraged intersection of law, economics, and public policy.

The Government of India’s recent approval of 29 additional proposals under the Electronics Component Manufacturing Scheme (ECMS)...

In Zydus Lifesciences Ltd. v. E.R. Squibb and Sons LLC & Ors. (FAO(OS) (COMM) 120/2025, CM APPL. 44383/2025, CM APPL. 44386/2025 & CM APPL. 44388/2025), the Division Bench of the Delhi High Court modified the interim order passed by the Single Judge, who had restrained Zydus from manufacturing, using, offering for sale, selling or importing its biosimilar version of the cancer immunotherapy drug Nivolumab in India.